Mild form of oculocutaneous albinism type 1: phenotypic analysis of compound heterozygous patients with the R402Q variant of the


Journal

The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041

Informations de publication

Date de publication:
09 2019
Historique:
received: 17 09 2018
revised: 23 10 2018
accepted: 08 11 2018
pubmed: 26 11 2018
medline: 21 3 2020
entrez: 26 11 2018
Statut: ppublish

Résumé

Oculocutaneous albinism type 1 (OCA1) is due to In our retrospective series, among 268 patients diagnosed with OCA1, 122 (45.5%) harboured one pathogenic variant of Most R402Q-OCA1 patients presented with white or yellow-white hair at birth (71.43%), blond hair later (46.97%), a light phototype but with residual pigmentation (69.64%), and blue eyes (76.56%). Their pigmentation was significantly higher than in the classical-OCA1 group. All patients from the R402Q-OCA1 group presented with ocular features of albinism. However the prevalence of photophobia (78.13%) and iris transillumination (83.87%) and the severity scores of iris transillumination, retinal hypopigmentation and foveal hypoplasia were lower in the R402Q-OCA1 group. Visual acuity was higher in the R402Q-OCA1 group (0.38±0.21 logarithm of the minimum angle of resolution vs 0.76±0.24). Investigations concerning a possible additive effect of the c.575C>A/p.Ser192 (S192Y) variant of The R402Q variant leads to variable but generally mild forms of albinism whose less typical presentation may lead to underdiagnosis.

Identifiants

pubmed: 30472657
pii: bjophthalmol-2018-312729
doi: 10.1136/bjophthalmol-2018-312729
doi:

Substances chimiques

Monophenol Monooxygenase EC 1.14.18.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1239-1247

Informations de copyright

© Author(s) (or their employer(s)) [year]. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Solene Monfermé (S)

Service d'ophtalmologie, CHU de Bordeaux, Bordeaux, France solene.monferme@hotmail.fr.

Eulalie Lasseaux (E)

Service de génétique médicale, CHU de Bordeaux, Bordeaux, France.

Catherine Duncombe-Poulet (C)

Cabinet d'ophtalmologie, rue du Château d'eau, Caen, France.

Christian Hamel (C)

Service d'ophtalmologie, Equipe maladies sensorielles génétiques, CHU de Montpellier, Montpellier, France.

Sabine Defoort-Dhellemmes (S)

Service d'exploration de la vision et neuro-ophtalmologie, CHRU de Lille, Lille, France.

Isabelle Drumare (I)

Service d'exploration de la vision et neuro-ophtalmologie, CHRU de Lille, Lille, France.

Xavier Zanlonghi (X)

Clinique ophtalmologique Sourdille, Nantes, France.

Hélène Dollfus (H)

Centre des affections rares en génétique ophtalmologique, CHU de Strasbourg, Strasbourg, France.

Yaurama Perdomo (Y)

Centre des affections rares en génétique ophtalmologique, CHU de Strasbourg, Strasbourg, France.

Dominique Bonneau (D)

Service de génétique, CHU d'Anger, Angers, France.

Jean-François Korobelnik (JF)

Service d'ophtalmologie, CHU de Bordeaux, Bordeaux, France.

Claudio Plaisant (C)

Service de génétique médicale, CHU de Bordeaux, Bordeaux, France.

Vincent Michaud (V)

Service de génétique médicale, CHU de Bordeaux, Bordeaux, France.

Perrine Pennamen (P)

Service de génétique médicale, CHU de Bordeaux, Bordeaux, France.
INSERM U1211, Maladies Rares, Génétique et Métabolisme, Université de Bordeaux, Bordeaux, France.

Caroline Rooryck-Thambo (C)

Service de génétique médicale, CHU de Bordeaux, Bordeaux, France.
INSERM U1211, Maladies Rares, Génétique et Métabolisme, Université de Bordeaux, Bordeaux, France.

Fanny Morice-Picard (F)

Service de dermatologie, Unité de dermato-pédiatrie du CHU de Bordeaux, Bordeaux, France.

Clement Paya (C)

Centre d'ophtalmologie du Palais Gallien, Bordeaux, France.

Benoit Arveiler (B)

Service de génétique médicale, CHU de Bordeaux, Bordeaux, France.
INSERM U1211, Maladies Rares, Génétique et Métabolisme, Université de Bordeaux, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH